2025 acc/aha hypertension guideline

Exposure

1 paper1 finding

  • 1 lab in 1 country
  • Humans1

Outcomes

1

Antihypertensive pharmacotherapy recommendation

upin humans1

1 study
  1. 2025 acc/aha hypertension guideline increases antihypertensive pharmacotherapy recommendation in humans (13.84% (95% CI, 7.06%-20.63%)).

    “13.84% (95% CI, 7.06%-20.63%) of untreated adults eligible under the Predicting Risk of Cardiovascular Disease Events threshold (0.42 million) became newly eligible for pharmacotherapy”

    Humansuntreated stage 1 hypertensionn = 1,926

    Guideline-Directed Treatment Eligibility and Burden of Untreated Stage-1 Hypertension Under the 2025 American College of Cardiology/American Heart Association Hypertension Guideline: Insights From NHANES 2015 to 2020

    Journal of the American Heart Association10 Oct 2026

Latest

Nov 2025: 0Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 11 in 12 months